Cytocell Ltd. today announced the availability of a new molecular cytogenetic test designed to identify the presence of gene rearrangements associated with a specific form of non-small-cell lung cancer (NSCLC). These rearrangements in a gene known as ROS1 (c-ros oncogene 1) have been implicated in the formation of cancerous tumors in patients with NSCLC. (Logo: http://photos.prnewswire.com/prnh/20120906/559436 ) Lung cancer is the world's leading cause of cancer death with more than 1.6 million
Survey of more than 15,000 physicians in 11 countries uncovers need for further educationThe Foundation for a Smoke-Free World invites researchers to propose new analysis...
Largest Worldwide Lung Cancer Research Organization Invites Global Collaborators to Attend Registration and abstract submission is now open for the International Association for the Study of Lung Cancer...
Not intended for UK-based media First of several registration trials expected to start in 2015 for the alliance between Merck and Pfizer Initiation and first...
Not intended for UK-based media Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1...
Recurrent lung cancer responds to Integrative Immunotherapy Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis....
Cytocell Ltd. announced the availability of a new range of in vitro diagnostic tests to aid in detecting patients with Chronic Lymphocytic Leukaemia (CLL), a cancer of the lymphocytes. (Logo: http://photos...
Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved an update to the label for ALIMTA(R) (pemetrexed for injection), adding...
This update outlines data from a preplanned analysis of the pivotal E4599 study in patients with non-small cell lung cancer (NSCLC), published in the Journal of Thoracic Oncology. The...
- For non-US, non-UK Media Only - Avastin Benefits Demonstrated in Combination With a Wide Range of Chemotherapies and in a Broad Patient Population New data show that...
- For non-US, non-UK Media Only - Phase II Study Points to Importance of EGFR Biomarker to Identify Patients who can Gain Exceptional Survival BenefitsNew data show that first-line treatment with Tarceva(R)(erlotinib)...
- Approval Would Allow Patients to Benefit From Earlier Use of Well-Tolerated Oral Treatment Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Committee for Medicinal Products for Human...
โรงพยาบาลไทยนครินทร์ จัดกิจกรรมรณรงค์เนื่องในวันมะเร็งปอด หรือ Lung Cancer Day ภายในงานได้มีการจัดบอร์ดนิทรรศการให้ความรู้การดูแลตนเองให้ห่างไกลจากโรคมะเร็งปอดและตั้งจุดบริการสืบค้นโอกาสเสี่ยงโดยใช้โปรแกรม Family Tree ผ่านระบบคอมพิวเตอร์ (จากภาพ) นพ.เจริญ มีนสุข...
- Phase III ATLAS Study Achieves a New Milestone in Treating Advanced Lung Cancer Roche announced today that the Phase III ATLAS study showed patients with advanced non...
ROCHE ANNOUNCES... BASEL: Roche and the Spanish Lung Cancer Group (SLCG) Friday announced their collaboration on the first phase III trial to investigate Tarceva (erlotinib) in lung cancer patients with genetic mutations in their...
- New Phase III Study Will Evaluate if Tarceva is Superior to Traditional Chemotherapy in First Line Treatment of key Group of Patients Roche and the Spanish Lung Cancer Group (SLCG) today announced their...